Using prescription digital therapeutics can lead to better outcomes for patients, making them a win-win for pharma and patients.
Tracey Dodenhoff, CEO of Medly Therapeutics, discusses her company's heart failure app and why pharma should consider prescription digital therapeutics among their offerings.
Novartis' Lutathera Shows Significant Survival Benefit as First-Line Treatment for GEP-NETs
January 19th 2024Lutathera plus long-acting release octreotide lowered the risk of disease progression or death by 72% in patients with somatostatin receptor-positive well-differentiated grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors.